The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...

Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...

The European drug authority recommends refusal of marketing authorization due to evidence gaps in quality and efficacy.

The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side effects ...

The drug failed to meet its primary endpoints in clinical trials, but subgroup analyses hinted at modest benefits.

The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.

The European Medicines Agency has granted orphan drug designation to narsoplimab for treatment in hematopoietic stem-cell transplant. About Hematopoietic stem cell transplant-associated thrombotic ...

About the author Chris Spivey is the editorial director of Pharmaceutical Technology Europe. Article details Pharmaceutical Technology Europe Volume 36, No. 2 February 2024 Pages 11–14 Citation When ...